FDA 483 - Biocon Limited - March 05, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Biocon Limited, a non-sterile API manufacturer in Bangalore, India, revealed significant deficiencies across multiple areas. Observations included discrepancies between submitted drug master file information and actual manufacturing processes, inadequate bacterial endotoxin testing and environmental monitoring, and failures in laboratory controls regarding chromatographic data and equipment calibration. Additionally, the quality unit failed to investigate a critical process deviation.
ID · 22848816-ba4b-4226-b8e4-859b1963ea4f